AVAiLABLE NIS – AVASTIN® in lung cancer treatment in routine oncology practice in Germany

BACKGROUND: Bevacizumab (Avastin®), a recombinant humanized monoclonal antibody, in combination with platinum-doublet chemotherapy has become a routine treatment for advanced non-small-cell lung cancer (NSCLC). The post-authorization, non-interventional study ‘AVAiLABLE’ assessed the effectiveness a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zahn, Mark-Oliver, Linck, Dominik, Losem, Christoph, Gessner, Christian, Metze, Holger, Gaillard, Vincent E., Tessen, Hans Werner
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511164/
https://www.ncbi.nlm.nih.gov/pubmed/31077164
http://dx.doi.org/10.1186/s12885-019-5618-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511164/
https://www.ncbi.nlm.nih.gov/pubmed/31077164
http://dx.doi.org/10.1186/s12885-019-5618-0

Ejemplares similares